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survivin and known regulators of apop-
tosis in the HF. Therefore, it would be
very interesting to further explore and/
or identify survivin upstream and down-
stream components in the control of
proliferation and apoptosis in the HF.
In summary, we provide the first
evidence that (1) survivin is expressed
in the proliferating keratinocytes of the
hair matrix and outer root sheath of
human anagen HF and its expression is
decreased with the progression of cata-
gen phase; (2) expression of survivin in
anagen HF may be controlled by Wnt/
b-catenin signaling. The dual functions
of survivin may be involved in the
control of the delicate proliferation–
apoptosis balance controlling HF cyclic
behavior.
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TO THE EDITOR
Genome-wide scanning and linkage
analysis were performed in three Chi-
nese families with disseminated super-
ficial actinic porokeratosis (DSAP) and
the gene was localized to an 8.0-cM
interval defined by D12S330 and
D12S354 on chromosome 12. Mean-
while, both missense mutations,
p.Ser63Asn in slingshot 1 (SSH1)
(Zhang et al., 2004) and a variation
(dbSNP3759383: G4A) in the promo-
Abbreviation: DSAP, disseminated superficial actinic porokeratosis; LOH, loss of heterozygosity;
SSH1, slingshot 1
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ter region of ARPC3 (Zhang et al.,
2005), were identified in Family 2. A
frameshift mutation, p.Ser19CysfsX24
in an alternative variant (isoform f) of
SSH1, was identified in Family 3
(Zhang et al., 2004). Do lesions deve-
lop based on haploinsufficiency of
SSH1 or does SSH1 function as a tumor
suppressor gene requiring inactivation
of the second, otherwise normal allele
in a given cell? Sequence analyses of
genomic DNA derived from lesional
tissues were performed to determine if a
second, acquired SSH1 mutation was
present, or whether there was drop out
of the wild-type sequence.
Deletion of the wild-type sequence
was observed at SSH1 in two of the
six lesional tissues, which were IV:3
and V:8 in Family 2 (Table 1). In
addition, loss of heterozygosity (LOH)
was found at ARPC3 in these two
lesional tissues. However, no allelic
loss was found in this region in other
matched samples. Figure 1 shows the
LOH sequences, for example, in
c.188G4A (p.Ser63Asn) at SSH1 and
Table 1. Clinical and molecular findings, including results of LOH analysis, in six patients with DSAP
No.
ID number in
the family we described Sex
Age
(years) Location Known SSH1 mutations1
LOH on
chromosome
12q
1 IV:3 in Family 2 F 53 Left forearm p.Ser63Asn +
2 IV:4 in Family 2 M 50 Left forearm p.Ser63Asn 
3 IV:8 in Family 2 M 49 Left forearm p.Ser63Asn 
4 IV:10 in Family 2 M 40 Chest p.Ser63Asn 
5 V:8 in Family 2 F 25 Left hand p.Ser63Asn +
6 III:2 in Family 3 F 23 Left ankle p.Ser19CysfsX24 in an
alternative variant (isoform f)

DSAP, disseminated superficial actinic porokeratosis; F, female; LOH, loss of heterozygosity; M, male; +, loss of heterozygosity; , no loss of heterozygosity.
1The amino-acid change within the SSH1 gene (Zhang et al., 2004).
C C C C C C A A A A A AGT T T T T T T T TC C C
A A A G A AGT T T T T T T T TC C C
A A A G A AGT T T T T T T T TC C C
AA A A AT T TG G G G C
C C C C C CAA A A AT T TG G G G C
C C C C C CAA A G AT T TG G G G C
199
199
199
181
181
181
Unaffected Unaffected
Normal
-appearing
Normal
-appearing
Lesional Lesional
− 812 − 794
− 812 − 794
− 812 − 794
a b
Figure 1. Chromatograms of the normal and mutated sequences and LOH in two affected members in Family 2. (a) NM_018984.2: c.188G4A (p.Ser63Asn)
at SSH1. (b) NM_005719.2: c. 804G4A (dbSNP3759383: G4A) at ARPC3 (The DNA numbering is based on cDNA sequence with a ‘‘c.’’ symbol before the
number.).
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c.804G4A (dbSNP3759383: G4A)
at ARPC3. Both patients were from the
same family, with close linked variation
in ARPC3 as reported previously (Zhang
et al., 2005). No difference was found
between DNA samples from the nor-
mal-appearing skin and peripheral
blood in the two patients with LOH at
SSH1 and ARPC3 by sequence analysis.
The loss of an allele from lesional tissue
in Figure 1a was not very pure, because
admixture with normal tissue may
constitute a major problem in LOH
studies (Tomlinson et al., 2002). The
genomic distance between SSH1 and
ARPC3 is approximately 1.58 Mb,
which is located between D12S1605
and D12S354 (Table 2).
Therefore, 10 highly polymorphic
microsatellite markers on spanning
chromosome 12q23–24.3 were selected
from Genethon Linkage Maps to define
the regions of LOH. The results of PCR-
based microsatellite analysis confirmed
the LOH we found in two of the
six lesional tissues, and the deleted
regions were also determined. Accord-
ing to Sequence Map on chromosome
12, the LOH region of IV:3 in Family 2
was 27.07 Mb, located from D12S1588
to D12S1679. The LOH region of V:8 in
Family 2 was 27.90 Mb, defined by
D12S78 and D12S1628 (Table 2).
D12S86 showed homozygosity in
all DNA samples from V:8 in Family
2, and did not provide reliable informa-
tion of LOH to this patient. Moreover,
no microsatellite instability was ob-
served in any of the paired DSAP
samples on chromosome 12q, and no
LOH was found in the samples ob-
tained from normal-appearing skin of
six patients.
So far, there are few studies on the
potential genetic mechanism leading to
the development of DSAP lesions. LOH
was considered to be a predictor to
map tumor suppressor genes in cancer,
and a powerful tool to gain a better
understanding of various skin diseases
(Happle, 1999; Thiagalingam et al.,
2002). As a rule, LOH is a genetic
mechanism by which a heterozygous
somatic cell becomes either homo-
zygous or hemizygous, originating from
a deletion, gene conversion, transloca-
tion, mitotic recombination, or non-
disjunction. The percentage of patients
with porokeratosis and associated
skin malignancies was estimated at
between 6.9 and 11.6% (Maubec
et al., 2005). Malignant transformation
has been reported to occur in 19% of
linear porokeratosis (Sasson and Krain,
1996). LOH or allelic loss was
proposed to explain the oncogenic
potential of linear porokeratosis (Hap-
ple, 1997). Moreover, it was taken
as segmental type 2 manifestation of
autosome-dominant skin diseases, used
to explain the coexistence of linear
porokeratosis and DSAP (Freyschmidt-
Paul et al., 1999). Because there were
no linear porokeratotic lesions super-
imposed on DSAP and no malignant
transformation in the pedigrees we
studied, our results could not show
a molecular proof for these genetic
concepts in DSAP. Neither microsatel-
lite instability nor allelic loss was
found in two lesional tissues of dis-
seminated superficial porokeratosis,
which was reported previously asso-
ciated with hereditary non-polyposis
colorectal cancer (Takata et al., 2000;
Hussein and Wood, 2002). To our
knowledge, our study is the first report
of LOH in DSAP lesions. The course
of disease and regions exposed to light
might affect the frequency of LOH,
but the haploinsufficiency of SSH1 in
lesions was not essential to develop
DSAP. It is speculated that normal-
appearing skin of some dermatoses
could be genetically altered by UV
exposure. In the literature, LOH in
histologically normal-appearing skin
was demonstrated in two of the 37
lesions of actinic keratosis (Kushida
et al., 1999); however, we did not find
LOH in adjacent normal-appearing skin
of DSAP in this study. The limited
number of samples and microsatellite
markers may account for this negative
result.
Table 2. LOH at microsatellite markers on chromosome12q in DSAP
IV:3 in Family 2 V:8 in Family 2
Marker Location (Mb) B N L B N L
D12S1588 100.26 HE HE HE HO HO HO
D12S78 102.79 HE HE LOH HE HE HE
D12S1605 107.23 HE HE LOH HE HE LOH
D12S354 113.61 HE HE LOH HE HE LOH
D12S86 117.65 HE HE LOH HO HO HO
D12S1612 123.47 HE HE LOH HE HE LOH
D12S1658 126.14 HE HE LOH HE HE LOH
D12S1679 127.33 HE HE HE HE HE LOH
D12S367 128.53 HE HE HE HE HE LOH
D12S1628 130.69 HE HE HE HE HE HE
B, blood; DSAP, disseminated superficial actinic porokeratosis; HE, heterozygous; HO, homozygous; L, lesional tissue; N, normal-appearing skin.
Note: Genetic coordinates in million base pairs (Mb) according to Sequence Map on Chromosome 12 are in column ‘‘Location’’.
Bold indicates the LOH region could be obvious.
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In summary, LOH was observed in
only two of the six lesions of DSAP, and
our results showed that the develop-
ment of DSAP lesions may sometimes
occur independently from LOH.
Whereas, LOH at the candidate region
might be a random event caused by
environment factors, such as sun
exposure.
Six adult patients were selected at
random from two DSAP families with
known SSH1 germline mutations,
which we reported before (Zhang
et al., 2004). These patients were IV:3,
4, 8, 10 and V:8 in Family 2 (S2) and
III:2 in Family 3 (S3), respectively.
Clinical data of Family 2 were de-
scribed in detail elsewhere (Zhang
et al., 2005). An overview of clinical
and molecular data of six patients from
two families is presented in Table 1.
The lesions with clear borderlines and
from mostly sun-exposed areas were
selected. With patients’ written in-
formed consent, lesional tissue and
adjacent normal-appearing skin were
dissected with a disposable scalpel
from each patient. All procedures were
approved by the ethical code of Fudan
University in accordance with the
Declaration of Helsinki Principles. The
paired samples were stored in RNAlater
(Qiagen, Germany) at 801C. After the
tissues were ground into powder in
liquid nitrogen, genomic DNA was
isolated by proteinase K-SDS lysis,
followed by phenol–chloroform extrac-
tion and ethanol precipitation. DNA
isolated from each patient’s peripheral
blood was used for control. DNA
sequence analysis of each lesional
tissue was compared with its matched
normal-appearing skin and blood. The
coding and the promoter regions of
SSH1 and ARPC3 were sequenced, as
described previously (Zhang et al.,
2004).
All of these markers were amplified
by multiplex PCR, as described pre-
viously (Zhang et al., 2004). The PCR
products were separated on a 3730xl
DNA Analyzer (Applied Biosystems,
Foster City, CA, USA), and GeneMap-
per software (v3.5) was used for gel
analysis and genotype assignment. Both
PCR and electrophoresis steps were
performed twice. LOH was visually
scored, and defined as a significant
reduction in peak intensity (484%) or
loss of one allele in lesional tissues
(Dieffenbach and Dveksler, 2003).
Microsatellite instability was defined
as a difference in length of amplified
microsatellite markers between the
blood and lesional tissue or adjacent
normal-appearing skin of the same
individual (Boland et al., 1998).
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